Measured Wealth Private Client Group LLC Has $581,000 Stock Holdings in Medtronic plc (NYSE:MDT)

Measured Wealth Private Client Group LLC lessened its holdings in Medtronic plc (NYSE:MDT) by 2.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,448 shares of the medical technology company’s stock after selling 150 shares during the quarter. Measured Wealth Private Client Group LLC’s holdings in Medtronic were worth $581,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of MDT. Fortitude Family Office LLC acquired a new stake in shares of Medtronic during the 3rd quarter valued at $27,000. Highline Wealth Partners LLC acquired a new stake in shares of Medtronic during the 3rd quarter valued at $27,000. Lynx Investment Advisory acquired a new stake in shares of Medtronic during the 2nd quarter valued at $28,000. Gleason Group Inc. acquired a new stake in shares of Medtronic during the 2nd quarter valued at $42,000. Finally, Opal Wealth Advisors LLC acquired a new stake in shares of Medtronic during the 2nd quarter valued at $43,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

MDT has been the topic of several recent research reports. Daiwa America raised Medtronic to a “strong-buy” rating in a report on Friday, August 23rd. Piper Sandler lifted their target price on Medtronic from $85.00 to $90.00 and gave the stock a “neutral” rating in a report on Wednesday, August 21st. Oppenheimer lifted their target price on Medtronic from $92.00 to $94.00 and gave the stock a “market perform” rating in a report on Wednesday, August 21st. Truist Financial lifted their target price on Medtronic from $90.00 to $93.00 and gave the stock a “hold” rating in a report on Monday, October 14th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Medtronic has an average rating of “Hold” and an average target price of $95.36.

Medtronic Stock Performance

Shares of Medtronic stock opened at $90.75 on Thursday. Medtronic plc has a one year low of $69.32 and a one year high of $92.68. The firm has a market capitalization of $116.37 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 2.60 and a beta of 0.84. The business has a 50-day simple moving average of $89.58 and a 200 day simple moving average of $84.03. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.13 and a quick ratio of 1.61.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The business had revenue of $7.97 billion during the quarter, compared to the consensus estimate of $7.90 billion. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.20 EPS. On average, research analysts anticipate that Medtronic plc will post 5.44 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 11th. Shareholders of record on Friday, September 27th were paid a dividend of $0.70 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $2.80 dividend on an annualized basis and a yield of 3.09%. Medtronic’s dividend payout ratio (DPR) is currently 101.82%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.